Fluorotechnics expands global capability via acquisition of ETC Elektrophorese-Technik
Fluorotechnics CEO, Duncan Veal, states, "We are very excited by the synergies that the combination of the two companies will bring. This acquisition will allow us to cross-sell products to existing customers and to address new markets utilizing our joint expertise. Our ever-expanding sales and marketing team and enormous potential for our product offering means that we are well positioned for strong growth."
The integrated company will retain its manufacturing bases in Sydney, Australia and Kirchentellinsfurt, Germany. Duncan Veal will continue as CEO, Hanspeter Schickle, CEO of ETC, will become head of product development in electrophoresis, and Günter Theßeling, a recent appointment from GE Healthcare, will spearhead the sales and marketing drive.
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.